急性早幼粒细胞白血病PML维甲酸受体α融合基因定量检测的应用价值  

Clinical application value of quantification of PML-RARα fusion gene in acute promyelocytic leukemia

作　　者：林纲[1] 陈蕾[1] 焦志军[1] 

机构地区：[1]江苏大学附属医院检验科,江苏镇江212001

出　　处：《检验医学与临床》2013年第10期1203-1204,1207,共3页Laboratory Medicine and Clinic

摘　　要：目的探讨早幼粒细胞白血病PML维甲酸受体α融合基因(PML-RARα)定量检测在急性早幼粒细胞白血病诊断、治疗中的临床应用价值。方法采用实时定量聚合酶链反应对12例急性早幼粒细胞白血病患者初诊、治疗后完全缓解及复发时PML-RARα进行定量检测,分析不同阶段其变化程度,并与同阶段细胞形态学、染色体分析进行比较。结果 12例急性早幼粒细胞白血病患者初发时PML-RARα均为阳性,完全缓解阶段转为阴性或定量结果呈逐渐下降趋势,当复发时PML-RARα再次并早于细胞形态学和染色体分析出现阳性,且定量结果明显高于初发阶段。结论 PML-RARα定量检测可为急性早幼粒细胞白血病诊断、治疗及提示复发提供可靠的依据。Objective To explore the clinical application value of quantification of PML-RARa fusion gene in the diagnosis and therapy of acute promyelocytic leukemia（APL）. Methods The PML-RARa fusion gene was quan- tified using real-time quantitative real time-polymerase chain reaction in 12 APL patients at initial diagnosis, complete remission and relapse. The levels of PML-RARa fusion gene, morphology and chromosomal alterations at different times were compared. Results PML-RARa fusion gene was positive in all 12 APL patients at initial diagnosis and decreased or turned negative at complete remission. PML-RARa fusion gene became positive again after relapse, which was earlier than the morphologic and chromosomal abnormalities. Furthermore, the levels of PML-RARa fu- sion gene at relapse were significantly higher than that at initial diagnosis. Conclusion The quantification of PML- RARa fusion gene could provide evidence for the diagnosis, therapy and relapse in APL.

关 键 词：急性早幼粒细胞白血病 早幼粒细胞白血病PML维甲酸受体α融合基因 聚合酶链反应 

分 类 号：R733.71[医药卫生—肿瘤]